ILT, as I have said in the past AMRN was ultimately a heart breaker, Luckly I took some off the table in the initial run up and made some $$$, but society will never benefit from what Vascepa can do for a person with cardiovascular disease. The company was cut off at the knees and has been left to struggle the rest of their existence. NWBO is a much different company with a much different product and its barriers to enter the market are much more complex than Vascepa, a generic company will not be able to just start producing DCVax. Thats the beauty of the NW Bio story and how LP and the team are building a fortress around what they are creating.
Market Data 
Markets 
AI
